We see tremendous opportunities in bringing the latest technologies for precision healthcare and discovery to Mars Petcare. Their dedication to targeted, preventative and individualized care is admirable, as well as their reach within the animal health community.
We are in a unique position to serve as the bridge between the data producers and the data users. We are absolutely delighted to work closely with the FinnGen team and bring our expertise, networks and scientific and technological developments to the project’s benefit.
Breakthroughs from the project will benefit health care systems and patients both locally and globally.
The study helps us find new areas for drug discovery and ways to prevent disease by tapping into decades of population-wide medical registry data and cutting-edge genomics expertise.
Microsoft’s focus on data security and regulatory compliance are perfectly matched with MediSapiens’ endeavors on bringing world class genomic, clinical and biomedical big data solutions to benefit healthcare facilities and clinical research not only in Finland but globally.
Having genomic data interpretation solutions on Microsoft Azure jointly with MediSapiens is a step forward in using the best technology available for improved healthcare services.
We are living in an exciting era where we can learn so much from increasing amounts of genomic, clinical and biomedical data through efficient data interpretation and analytics solutions.
Our project will make a substantial contribution in updating the dog genetic map. This will help to identify disease-associated genetic alterations and enable their efficient comparison with the human genome.
The project also builds on substantial previous research and a large dog biobank, and supports other ongoing initiatives, such as the international 10,000 Dog Genomes Project.
We’re dedicated to participate in scientific initiatives which have the potential to make significant improvements in our understanding of health and disease, and eventually contribute to improvements in human healthcare.
In 2016, selecting the top achievers was by no means a small feat. In fact, we had the toughest time in years because so many entrepreneurs had crossed significant milestones so early. But after much thought, rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across Europe to the Top 100 Winners. We believe MediSapiens embodies the vision, drive and innovation that define a successful entrepreneurial venture. MediSapiens should be proud of its accomplishment, as the competition was very strong..
We are excited and honored to win this award, demonstrating the strength of our offering and strategy.
This recognition solidifies our position in providing intuitive, science-backed tools for effective utilization of the vast amount of genomic, biomedical and clinical data that is gathered all around the world. We continue on this path and are committed to help our customers gain success and growth in their business and research endeavors.
Our consortium has the potential for smooth development and application in Estonia and elsewhere.
We are very excited to be part of such a strong consortium with an important aim of improving healthcare processes and health of individuals through novel personalized medicine tools.
The project is excellently aligned with our goals to serve the consumer and professional medical and clinical sectors comprehensively.
The new method enables producing large amounts of biological data. Utilizing it in practical every day patient care requires sophisticated data management and correct interpretation.
The core competence of MediSapiens is in creating custom-made solutions to process complex biological data for research and health care purposes. Genomic information offers unlimited possibilities, of which the development of personalized medicine is an excellent example.